For Quick Alerts
For Daily Alerts

Natco Pharma Plunges 11% As Company Receives 483 US FDA Observations


Shares in Natco Pharma plunged as much as 11 per cent, after the company said that it has received 483 observations from the US FDA.

The stock of Natco Pharma last trading at Rs 417, down 11.1 per cent in trade.

Natco Pharma Plunges 11% As Company Receives 483 US FDA Observations
"An inspection was conducted by the United States Food & Drug Administration (USFDA) in two of its manufacturing facilities recently- the Active Pharmaceutical Ingredients (API) manufacturing facility at Manali, near Chennai, and thePharmaceutical Formulations facility at Kothur, near Hyderabad, during early February and March, 2016, respectively.

The company has received 483 observations for both facilities and believes them to be of minor in nature. The company has already sent response and compliance report for these observations and believes that there would be no adverse impact to its current or future pipeline products coming from these facilities," it said in a release to the exchanges.

Read more about: natco us fda
Story first published: Monday, March 28, 2016, 10:45 [IST]
Company Search
Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'


We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more